| Glenn M Preminger, MD | |
|
2100 Erwin Road, Durham, NC 27710-0001 | |
| (919) 620-4467 | |
| Not Available |
| Full Name | Glenn M Preminger |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 47 Years |
| Location | 2100 Erwin Road, Durham, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255415147 | NPI | - | NPPES |
| 8969032 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 22612 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Duke University Hospital | Durham, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duke Health Integrated Practice Inc | 8325412737 | 2551 |
News Archive
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
The Navajo Area Indian Health Service and the Northern Arizona Veterans Affairs Health Care System recently signed an agreement that aims to improve access to post-traumatic stress disorder treatment for war veterans, the Farmington Daily Times reports.
Anulex Technologies, Inc., a privately held medical device manufacturer focusing on soft tissue Preservation & Anular Repair products, announced the first closing of its fifth round of private equity financing which will total a minimum of $20 million. The Series E round was led by a new unnamed strategic investor with participation from existing investors Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.
The morning coffee or tea can perk one up for the day, however, for some of us these beverages are too bitter. Researchers have now found that the bitter taste experienced is all down to genes. The new study titled, "Understanding the role of bitter taste perception in coffee, tea and alcohol consumption through Mendelian randomization," was published in the latest issue of the journal Nature Scientific Reports.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the results of recent testing of the unique PVA film formulation produced by Lanzhou Sanhuan New Technology Development Ltd. of Ganzu, China. Earlier this week, Biomagnetics announced its intent to acquire Lanzhou as the first of several planned acquisitions to be done at a $1.00 share price valuation for Biomagnetics Diagnostics' common shares.
› Verified 9 days ago
| Entity Name | Private Diagnostic Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457389033 PECOS PAC ID: 1355254368 Enrollment ID: O20031204000577 |
News Archive
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
The Navajo Area Indian Health Service and the Northern Arizona Veterans Affairs Health Care System recently signed an agreement that aims to improve access to post-traumatic stress disorder treatment for war veterans, the Farmington Daily Times reports.
Anulex Technologies, Inc., a privately held medical device manufacturer focusing on soft tissue Preservation & Anular Repair products, announced the first closing of its fifth round of private equity financing which will total a minimum of $20 million. The Series E round was led by a new unnamed strategic investor with participation from existing investors Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.
The morning coffee or tea can perk one up for the day, however, for some of us these beverages are too bitter. Researchers have now found that the bitter taste experienced is all down to genes. The new study titled, "Understanding the role of bitter taste perception in coffee, tea and alcohol consumption through Mendelian randomization," was published in the latest issue of the journal Nature Scientific Reports.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the results of recent testing of the unique PVA film formulation produced by Lanzhou Sanhuan New Technology Development Ltd. of Ganzu, China. Earlier this week, Biomagnetics announced its intent to acquire Lanzhou as the first of several planned acquisitions to be done at a $1.00 share price valuation for Biomagnetics Diagnostics' common shares.
› Verified 9 days ago
| Entity Name | Duke Health Integrated Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
The Navajo Area Indian Health Service and the Northern Arizona Veterans Affairs Health Care System recently signed an agreement that aims to improve access to post-traumatic stress disorder treatment for war veterans, the Farmington Daily Times reports.
Anulex Technologies, Inc., a privately held medical device manufacturer focusing on soft tissue Preservation & Anular Repair products, announced the first closing of its fifth round of private equity financing which will total a minimum of $20 million. The Series E round was led by a new unnamed strategic investor with participation from existing investors Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.
The morning coffee or tea can perk one up for the day, however, for some of us these beverages are too bitter. Researchers have now found that the bitter taste experienced is all down to genes. The new study titled, "Understanding the role of bitter taste perception in coffee, tea and alcohol consumption through Mendelian randomization," was published in the latest issue of the journal Nature Scientific Reports.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the results of recent testing of the unique PVA film formulation produced by Lanzhou Sanhuan New Technology Development Ltd. of Ganzu, China. Earlier this week, Biomagnetics announced its intent to acquire Lanzhou as the first of several planned acquisitions to be done at a $1.00 share price valuation for Biomagnetics Diagnostics' common shares.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Glenn M Preminger, MD 5213 S Alston Avenue, Durham, NC 27713-4430 Ph: (919) 684-8111 | Glenn M Preminger, MD 2100 Erwin Road, Durham, NC 27710-0001 Ph: (919) 620-4467 |
News Archive
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
The Navajo Area Indian Health Service and the Northern Arizona Veterans Affairs Health Care System recently signed an agreement that aims to improve access to post-traumatic stress disorder treatment for war veterans, the Farmington Daily Times reports.
Anulex Technologies, Inc., a privately held medical device manufacturer focusing on soft tissue Preservation & Anular Repair products, announced the first closing of its fifth round of private equity financing which will total a minimum of $20 million. The Series E round was led by a new unnamed strategic investor with participation from existing investors Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.
The morning coffee or tea can perk one up for the day, however, for some of us these beverages are too bitter. Researchers have now found that the bitter taste experienced is all down to genes. The new study titled, "Understanding the role of bitter taste perception in coffee, tea and alcohol consumption through Mendelian randomization," was published in the latest issue of the journal Nature Scientific Reports.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the results of recent testing of the unique PVA film formulation produced by Lanzhou Sanhuan New Technology Development Ltd. of Ganzu, China. Earlier this week, Biomagnetics announced its intent to acquire Lanzhou as the first of several planned acquisitions to be done at a $1.00 share price valuation for Biomagnetics Diagnostics' common shares.
› Verified 9 days ago
Dr. Karen Christine Baker, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 5704 Fayetteville Rd, Durham, NC 27713 Phone: 919-572-4673 Fax: 919-668-0321 | |
Tom Spalding, P.A. Urology Medicare: Not Enrolled in Medicare Practice Location: 205 Frasier St, Triangle Urology Associates, P.a., Durham, NC 27704 Phone: 919-477-7003 Fax: 919-471-2827 | |
Dr. Thomas James Polascik, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: Duke Cancer Center 5-1 Urology, Duke Cancer Center, Duke University Medical Center, Durham, NC 27710 Phone: 919-684-4946 Fax: 919-684-5220 | |
Brant A Inman, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1000 Trent Dr, Durham, NC 27710 Phone: 919-684-8111 | |
Dr. Andrew Charles Peterson, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 40 Duke Medicine Cir, Durham, NC 27710 Phone: 919-684-2516 | |
Judd Moul, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2100 Erwin Rd, Durham, NC 27710 Phone: 919-620-4467 | |
Daniel George, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: Duke University Medical Ctr, Durham, NC 27710 Phone: 919-620-4467 |